首页 > 最新文献

Chinese Journal of Cancer Research最新文献

英文 中文
Comments on Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version) 中国黑色素瘤诊疗指南2018(英文版)
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2019-10-01 DOI: 10.21147/j.issn.1000-9604.2019.05.03
X. Bai, L. Mao, Jun Guo
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China Correspondence to: Jun Guo. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China. Email: guoj307@126.com.
北京大学肿瘤医院肿瘤研究所,癌变与转化研究教育部重点实验室,肾癌与黑色素瘤科,北京100142北京大学肿瘤医院肿瘤研究所肾癌与黑色素瘤科癌变与转化研究教育部重点实验室,北京100142电子邮件:guoj307@126.com。
{"title":"Comments on Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version)","authors":"X. Bai, L. Mao, Jun Guo","doi":"10.21147/j.issn.1000-9604.2019.05.03","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2019.05.03","url":null,"abstract":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China Correspondence to: Jun Guo. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China. Email: guoj307@126.com.","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"31 1","pages":"740 - 741"},"PeriodicalIF":5.1,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44144269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients 曲妥珠单抗联合辅助化疗治疗人表皮生长因子受体2(HER2)阳性的早期癌症:中国患者的现实世界回顾性研究
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2019-10-01 DOI: 10.21147/j.issn.1000-9604.2019.05.06
Jihong Guo, Qing Li, Pin Zhang, P. Yuan, Jiayu Wang, F. Ma, Ying Fan, R. Cai, Yang Luo, Qiao Li, Bing-he Xu
Objective To assess the long-term effectiveness and safety of trastuzumab in adjuvant therapy for Chinese patients with early-stage human epidermal growth factor 2 (HER2)-positive breast cancer in a real-world setting. Methods This retrospective observational study analyzed the medical records of HER2-positive breast cancer patients between 2000 and 2012 at the Chinese Academy of Medical Sciences. Patients who received adjuvant chemotherapy alone or adjuvant chemotherapy followed by/combined with trastuzumab were included. The Kaplan-Meier method was used to estimate disease-free survival (DFS) and overall survival (OS). Hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated using the Cox regression model. Results Of the 1,348 patients analyzed, 909 received chemotherapy alone and 439 received chemotherapy plus trastuzumab. The 3-year, 5-year and 10-year DFS rates were 83.70%, 76.38% and 68.94%, respectively, in the chemotherapy-alone cohort, and 90.21%, 86.19% and 83.45% in the chemotherapy plus trastuzumab cohort. The 3-year, 5-year and 10-year OS rates were 96.10%, 91.40% and 81.88% in the chemotherapy-alone cohort, and 98.17%, 94.91% and 90.01% in the chemotherapy plus trastuzumab cohort. The chemotherapy plus trastuzumab group had a significantly lower risk of disease recurrence and death than the chemotherapy-alone group (DFS: HR=0.50, 95% CI, 0.37−0.68; P<0.001; OS: HR=0.53, 95% CI, 0.34−0.81; P=0.004) after adjusting for covariates. In the 439 patients treated with trastuzumab, multivariate analysis suggested that lymph node positivity, higher T stages, and hormone receptor-negative status were significantly associated with higher risks of disease recurrence, and lymph node positivity and hormone receptor-negative status were significantly associated with higher risks of death. Grade 3/4 adverse events (incidence ≥1%) were more common in patients receiving trastuzumab (54.44%vs. 15.73%). Conclusions Early-stage HER2-positive breast cancer patients treated with trastuzumab plus adjuvant chemotherapy have a significant survival benefit compared with chemotherapy-alone in real-world settings. Lymph node positivity, hormone receptor-negative status, and higher T stages may be associated with higher risks of recurrence, and effective therapy for patients with these factors is required.
目的评价曲妥珠单抗辅助治疗早期人表皮生长因子2(HER2)阳性癌症的长期有效性和安全性。方法回顾性观察分析中国医学科学院2000~2012年间HER2阳性乳腺癌症患者的病历资料。纳入接受单独辅助化疗或辅助化疗后/联合曲妥珠单抗的患者。Kaplan-Meier方法用于估计无病生存期(DFS)和总生存期(OS)。使用Cox回归模型计算危险比(HR)和95%置信区间(95%CI)。结果在分析的1348例患者中,909例接受单独化疗,439例接受化疗加曲妥珠单抗。单独化疗组的3年、5年和10年DFS发生率分别为83.70%、76.38%和68.94%,化疗加曲妥珠单抗组的DFS发生率为90.21%、86.19%和83.45%。单化疗组的3年、5年和10年OS发生率分别为96.10%、91.40%和81.88%,化疗加曲妥珠单抗组的OS发生率为98.17%、94.91%和90.01%。经协变量调整后,化疗加曲妥珠单抗组的疾病复发和死亡风险显著低于单独化疗组(DFS:HR=0.50,95%CI,0.37−0.68;P<0.001;OS:HR=0.53,95%CI;0.34−0.81;P=0.004)。在439名接受曲妥珠单抗治疗的患者中,多变量分析表明,淋巴结阳性、T分期较高和激素受体阴性状态与疾病复发的较高风险显著相关,而淋巴结阳性和激素受体阳性状态与死亡的较高风险显着相关。3/4级不良事件(发生率≥1%)在接受曲妥珠单抗治疗的患者中更常见(54.44%对15.73%)。淋巴结阳性、激素受体阴性和较高的T分期可能与较高的复发风险有关,需要对有这些因素的患者进行有效治疗。
{"title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients","authors":"Jihong Guo, Qing Li, Pin Zhang, P. Yuan, Jiayu Wang, F. Ma, Ying Fan, R. Cai, Yang Luo, Qiao Li, Bing-he Xu","doi":"10.21147/j.issn.1000-9604.2019.05.06","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2019.05.06","url":null,"abstract":"Objective To assess the long-term effectiveness and safety of trastuzumab in adjuvant therapy for Chinese patients with early-stage human epidermal growth factor 2 (HER2)-positive breast cancer in a real-world setting. Methods This retrospective observational study analyzed the medical records of HER2-positive breast cancer patients between 2000 and 2012 at the Chinese Academy of Medical Sciences. Patients who received adjuvant chemotherapy alone or adjuvant chemotherapy followed by/combined with trastuzumab were included. The Kaplan-Meier method was used to estimate disease-free survival (DFS) and overall survival (OS). Hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated using the Cox regression model. Results Of the 1,348 patients analyzed, 909 received chemotherapy alone and 439 received chemotherapy plus trastuzumab. The 3-year, 5-year and 10-year DFS rates were 83.70%, 76.38% and 68.94%, respectively, in the chemotherapy-alone cohort, and 90.21%, 86.19% and 83.45% in the chemotherapy plus trastuzumab cohort. The 3-year, 5-year and 10-year OS rates were 96.10%, 91.40% and 81.88% in the chemotherapy-alone cohort, and 98.17%, 94.91% and 90.01% in the chemotherapy plus trastuzumab cohort. The chemotherapy plus trastuzumab group had a significantly lower risk of disease recurrence and death than the chemotherapy-alone group (DFS: HR=0.50, 95% CI, 0.37−0.68; P<0.001; OS: HR=0.53, 95% CI, 0.34−0.81; P=0.004) after adjusting for covariates. In the 439 patients treated with trastuzumab, multivariate analysis suggested that lymph node positivity, higher T stages, and hormone receptor-negative status were significantly associated with higher risks of disease recurrence, and lymph node positivity and hormone receptor-negative status were significantly associated with higher risks of death. Grade 3/4 adverse events (incidence ≥1%) were more common in patients receiving trastuzumab (54.44%vs. 15.73%). Conclusions Early-stage HER2-positive breast cancer patients treated with trastuzumab plus adjuvant chemotherapy have a significant survival benefit compared with chemotherapy-alone in real-world settings. Lymph node positivity, hormone receptor-negative status, and higher T stages may be associated with higher risks of recurrence, and effective therapy for patients with these factors is required.","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"31 1","pages":"759 - 770"},"PeriodicalIF":5.1,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49295976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Chinese guidelines for diagnosis and treatment of gastric cancer 2018 (English version) 中国胃癌诊疗指南2018(英文版)
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2019-10-01 DOI: 10.21147/j.issn.1000-9604.2019.05.01
National Health Commission of PRC
1. Overview 2. Diagnosis 2.1 Symptoms 2.2 Signs 2.3 Imaging 2.3.1 X-ray gas-barium double-contrast imaging 2.3.2 Ultrasonography (US) 2.3.3 CT 2.3.4 MRI 2.3.5 Positron emission tomography (PET)-CT 2.3.6 Emission computerized tomography (ECT) 2.3.7 Tumor biomarkers 2.3.8 Endoscopy 2.3.9 EUS 2.4 Diagnostic criteria and contents of gastric cancer 2.4.1 Qualitative diagnosis 2.4.2 Staging diagnosis 2.4.3 Clinical manifestations 2.5 Differential diagnosis 2.5.1 Benign gastric ulcer 2.5.2 Gastric lymphoma 2.5.3 Gastrointestinal stromal tumor 2.5.4 Neuroendocrine neoplasm (NEN) 2.5.5 Benign gastric tumor 3. Pathology specification 3.1 Terms and definitions 3.1.1 Gastric carcinoma 3.1.2 Intraepithelial neoplasia/dysplasia 3.1.3 Early gastric carcinoma 3.1.4 Advanced gastric carcinoma 3.1.5 Adenocarcinoma of EGJ 3.2 Specimen type and fixation 3.2.1 Specimen type 3.2.2 Specimen fixation 3.3 Norm of handling and describing specimens 3.3.1 Handling of biopsy specimen 3.3.2 Handling of endoscopically resected specimens (EMR/ESD) 3.3.3 Handling of resected specimen 3.4 Classification, grade and staging of pathological diagnosis 3.4.1 Histological type (Appendix 3) 3.4.2 Histological grade 3.4.3 Gastric cancer staging 3.4.4 Pathological evaluation of radical resection specimens after neoadjuvant therapy (Appendix 4) 3.5
1. 概述2。诊断2.1症状2.2体征2.3影像学检查2.3.1 x线气钡双对比成像2.3.2超声检查(US) 2.3.3 CT 2.3.4 MRI 2.3.5正电子发射断层扫描(PET)-CT 2.3.6放射断层扫描(ECT) 2.3.7肿瘤生物标志物2.3.8内镜检查2.3.9 EUS 2.4胃癌诊断标准及内容2.4.1定性诊断2.4.2分期诊断2.4.3临床表现2.5鉴别诊断2.5.1良性胃溃疡2.5.2胃淋巴瘤2.5.3胃肠道间质瘤2.5.4神经内分泌瘤2.5.5胃良性肿瘤3.1术语与定义3.1.1胃癌3.1.2上皮内瘤变/不典型增生3.1.3早期胃癌3.1.4晚期胃癌3.1.5 EGJ腺癌3.2标本类型及固定3.2.1标本类型3.2.2标本固定3.3标本处理及描述规范3.3.1活检标本处理3.3.2内镜切除标本处理(EMR/ESD) 3.3.3切除标本处理3.4分类3.4.1组织学分型(附件3)3.4.2组织学分级3.4.3胃癌分期3.4.4新辅助治疗后根治标本的病理评价(附件4
{"title":"Chinese guidelines for diagnosis and treatment of gastric cancer 2018 (English version)","authors":"National Health Commission of PRC","doi":"10.21147/j.issn.1000-9604.2019.05.01","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2019.05.01","url":null,"abstract":"1. Overview 2. Diagnosis 2.1 Symptoms 2.2 Signs 2.3 Imaging 2.3.1 X-ray gas-barium double-contrast imaging 2.3.2 Ultrasonography (US) 2.3.3 CT 2.3.4 MRI 2.3.5 Positron emission tomography (PET)-CT 2.3.6 Emission computerized tomography (ECT) 2.3.7 Tumor biomarkers 2.3.8 Endoscopy 2.3.9 EUS 2.4 Diagnostic criteria and contents of gastric cancer 2.4.1 Qualitative diagnosis 2.4.2 Staging diagnosis 2.4.3 Clinical manifestations 2.5 Differential diagnosis 2.5.1 Benign gastric ulcer 2.5.2 Gastric lymphoma 2.5.3 Gastrointestinal stromal tumor 2.5.4 Neuroendocrine neoplasm (NEN) 2.5.5 Benign gastric tumor 3. Pathology specification 3.1 Terms and definitions 3.1.1 Gastric carcinoma 3.1.2 Intraepithelial neoplasia/dysplasia 3.1.3 Early gastric carcinoma 3.1.4 Advanced gastric carcinoma 3.1.5 Adenocarcinoma of EGJ 3.2 Specimen type and fixation 3.2.1 Specimen type 3.2.2 Specimen fixation 3.3 Norm of handling and describing specimens 3.3.1 Handling of biopsy specimen 3.3.2 Handling of endoscopically resected specimens (EMR/ESD) 3.3.3 Handling of resected specimen 3.4 Classification, grade and staging of pathological diagnosis 3.4.1 Histological type (Appendix 3) 3.4.2 Histological grade 3.4.3 Gastric cancer staging 3.4.4 Pathological evaluation of radical resection specimens after neoadjuvant therapy (Appendix 4) 3.5","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"31 1","pages":"707 - 737"},"PeriodicalIF":5.1,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41348720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 80
A study on service capacity of primary medical and health institutions for cervical cancer screening in urban and rural areas in China 中国城乡基层医疗卫生机构癌症筛查服务能力研究
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2019-10-01 DOI: 10.21147/j.issn.1000-9604.2019.05.13
Yang Li, Li Ma, Chunxia Yang, Zhang Chen, Yuqian Zhao, L. Dang, J. Lang, Y. Qiao
Objective To provide a decision-making basis for sustainable and effective development of cervical cancer screening. Methods This cross-sectional study assesses the service capacity to conduct cervical cancer screening with a sample of 310 medical staff, medical institutions and affiliated township health centers from 20 county-level/district-level areas in 14 Chinese provinces in 2016. Results The county-level/district-level institutions were the main prescreening institutions for cervical cancer screening. More medical staff have become engaged in screening, with a significantly higher amounts in urban than in rural areas (P<0.05). The number of human papillomavirus (HPV) testers grew the fastest (by 225% in urban and 125% in rural areas) over the course of the project. HPV testing took less time than cytology to complete the same number of screening tasks in both urban and rural areas. The proportion of mid-level professionals was the highest among the medical staff, 40.0% in urban and 44.7% in rural areas (P=0.406), and most medical staff had a Bachelor’s degree, accounting for 76.3% in urban and 52.0% in rural areas (P<0.001). In urban areas, 75.0% were qualified medical staff, compared with 68.0% in rural areas, among which the lowest proportion was observed for rural cytology inspectors (22.7%). The medical equipment for cervical pathology diagnosis in urban areas was better (P<0.001). HPV testing equipment was relatively adequate (typing test equipment was 70% in urban areas, and non-typing testing equipment was 70% in rural areas). Conclusions The service capacity of cervical cancer screening is insufficient for the health needs of the Chinese population. HPV testing might be an optimal choice to fill the needs of cervical cancer screening given current Chinese medical health service capacity.
目的为癌症筛查的可持续有效发展提供决策依据。方法本横断面研究以2016年中国14个省20个县(区)的310名医务人员、医疗机构和附属乡镇卫生院为样本,评估癌症筛查的服务能力。结果县级/区级机构是癌症筛查的主要预筛选机构。越来越多的医务人员参与了筛查,城市的筛查人数明显高于农村地区(P<0.05)。在项目过程中,人乳头瘤病毒(HPV)检测人数增长最快(城市增长225%,农村增长125%)。在城市和农村地区,HPV检测比细胞学检查花费更少的时间来完成相同数量的筛查任务。中级专业人员在医务人员中所占比例最高,城市为40.0%,农村为44.7%(P=0.406),大多数医务人员具有学士学位,城市为76.3%,农村为52.0%(P<0.001),其中农村细胞学检查的比例最低(22.7%),城市地区宫颈病理诊断的医疗设备较好(P<0.001),HPV检测设备相对充足(城市地区分型检测设备占70%,农村地区非分型检测仪器占70%)。结论癌症筛查服务能力不足以满足我国人群的健康需求。鉴于目前中国的医疗卫生服务能力,HPV检测可能是满足癌症筛查需求的最佳选择。
{"title":"A study on service capacity of primary medical and health institutions for cervical cancer screening in urban and rural areas in China","authors":"Yang Li, Li Ma, Chunxia Yang, Zhang Chen, Yuqian Zhao, L. Dang, J. Lang, Y. Qiao","doi":"10.21147/j.issn.1000-9604.2019.05.13","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2019.05.13","url":null,"abstract":"Objective To provide a decision-making basis for sustainable and effective development of cervical cancer screening. Methods This cross-sectional study assesses the service capacity to conduct cervical cancer screening with a sample of 310 medical staff, medical institutions and affiliated township health centers from 20 county-level/district-level areas in 14 Chinese provinces in 2016. Results The county-level/district-level institutions were the main prescreening institutions for cervical cancer screening. More medical staff have become engaged in screening, with a significantly higher amounts in urban than in rural areas (P<0.05). The number of human papillomavirus (HPV) testers grew the fastest (by 225% in urban and 125% in rural areas) over the course of the project. HPV testing took less time than cytology to complete the same number of screening tasks in both urban and rural areas. The proportion of mid-level professionals was the highest among the medical staff, 40.0% in urban and 44.7% in rural areas (P=0.406), and most medical staff had a Bachelor’s degree, accounting for 76.3% in urban and 52.0% in rural areas (P<0.001). In urban areas, 75.0% were qualified medical staff, compared with 68.0% in rural areas, among which the lowest proportion was observed for rural cytology inspectors (22.7%). The medical equipment for cervical pathology diagnosis in urban areas was better (P<0.001). HPV testing equipment was relatively adequate (typing test equipment was 70% in urban areas, and non-typing testing equipment was 70% in rural areas). Conclusions The service capacity of cervical cancer screening is insufficient for the health needs of the Chinese population. HPV testing might be an optimal choice to fill the needs of cervical cancer screening given current Chinese medical health service capacity.","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"31 1","pages":"838 - 848"},"PeriodicalIF":5.1,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47371415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Machine-learning-assisted prediction of surgical outcomes in patients undergoing gastrectomy 机器学习辅助预测胃切除术患者的手术结果
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2019-10-01 DOI: 10.21147/j.issn.1000-9604.2019.05.09
Sheng Lu, M. Yan, Chen Li, Chao Yan, Zheng‐gang Zhu, Wencong Lu
Objective Postoperative complications adversely affected the prognosis in patients with gastric cancer. This study intends to investigate the feasibility of using machine-learning model to predict surgical outcomes in patients undergoing gastrectomy. Methods In this study, cancer patients who underwent gastrectomy at Shanghai Rui Jin Hospital in 2017 were randomly assigned to a development or validation cohort in a 9:1 ratio. A support vector classification (SVC) model to predict surgical outcomes in patients undergoing gastrectomy was developed and further validated. Results A total of 321 patients with 32 features were collected. The positive and negative outcomes of postoperative complication after gastrectomy appeared in 100 (31.2%) and 221 (68.8%) patients, respectively. The SVC model was constructed to predict surgical outcomes in patients undergoing gastrectomy. The accuracy of 10-fold cross validation and external verification was 78.17% and 78.12%, respectively. Further, an online web server has been developed to share the SVC model for machine-learning-assisted prediction of surgical outcomes in patients undergoing gastrectomy in the future procedures, which is accessible at the web address: http://47.100.47.97:5005/r_model_prediction. Conclusions The SVC model was a useful predictor for measuring the risk of postoperative complications after gastrectomy, which may help stratify patients with different overall status for choice of surgical procedure or other treatments. It can be expected that machine-learning models in cancer informatics research are possibly shareable and accessible via web address all over the world.
目的癌症患者术后并发症对预后的影响。本研究旨在探讨使用机器学习模型预测胃切除术患者手术结果的可行性。方法将2017年在上海瑞金医院接受胃切除术的癌症患者按9:1的比例随机分为开发或验证队列。开发并进一步验证了一种用于预测胃切除术患者手术结果的支持向量分类(SVC)模型。结果共收集321例患者,32个特征。胃切除术后并发症的阳性和阴性结果分别出现在100例(31.2%)和221例(68.8%)患者中。SVC模型用于预测胃切除术患者的手术结果。10倍交叉验证和外部验证的准确率分别为78.17%和78.12%。此外,已经开发了一个在线网络服务器来共享SVC模型,该模型用于机器学习辅助预测未来手术中接受胃切除术的患者的手术结果,该模型可在以下网址访问:http://47.100.47.97:5005/r_model_prediction.结论SVC模型是衡量胃切除术后并发症风险的有用预测指标,有助于对不同整体状态的患者进行分层,以选择手术或其他治疗方法。可以预期,癌症信息学研究中的机器学习模型可能是可共享的,并且可以通过世界各地的网址访问。
{"title":"Machine-learning-assisted prediction of surgical outcomes in patients undergoing gastrectomy","authors":"Sheng Lu, M. Yan, Chen Li, Chao Yan, Zheng‐gang Zhu, Wencong Lu","doi":"10.21147/j.issn.1000-9604.2019.05.09","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2019.05.09","url":null,"abstract":"Objective Postoperative complications adversely affected the prognosis in patients with gastric cancer. This study intends to investigate the feasibility of using machine-learning model to predict surgical outcomes in patients undergoing gastrectomy. Methods In this study, cancer patients who underwent gastrectomy at Shanghai Rui Jin Hospital in 2017 were randomly assigned to a development or validation cohort in a 9:1 ratio. A support vector classification (SVC) model to predict surgical outcomes in patients undergoing gastrectomy was developed and further validated. Results A total of 321 patients with 32 features were collected. The positive and negative outcomes of postoperative complication after gastrectomy appeared in 100 (31.2%) and 221 (68.8%) patients, respectively. The SVC model was constructed to predict surgical outcomes in patients undergoing gastrectomy. The accuracy of 10-fold cross validation and external verification was 78.17% and 78.12%, respectively. Further, an online web server has been developed to share the SVC model for machine-learning-assisted prediction of surgical outcomes in patients undergoing gastrectomy in the future procedures, which is accessible at the web address: http://47.100.47.97:5005/r_model_prediction. Conclusions The SVC model was a useful predictor for measuring the risk of postoperative complications after gastrectomy, which may help stratify patients with different overall status for choice of surgical procedure or other treatments. It can be expected that machine-learning models in cancer informatics research are possibly shareable and accessible via web address all over the world.","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"31 1","pages":"797 - 805"},"PeriodicalIF":5.1,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44062669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Effect of intraoperative fluid administration on perioperative outcomes in patients undergoing McKeown esophagogastrectomy 术中给液对McKeown食管胃切除术患者围手术期预后的影响
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2019-10-01 DOI: 10.21147/j.issn.1000-9604.2019.05.04
Hongliang Wu, Wen Wang, Gefei Zhao, Q. Xue
Objective Fluid therapy is one of the key components of perioperative management. However, evidence of intraoperative fluid (IOF) administration affecting clinical outcomes following McKeown esophagogastrectomy remains limited. This study investigated the impact of IOF on clinical outcomes after McKeown esophagogastrectomy. Methods Patients who underwent McKeown esophagogastrectomy between July 2013 and July 2016 were identified. Preoperative, intraoperative and postoperative variables for each eligible patient were retrospectively collected from our electronic medical records and anesthetic records. IOF rates were determined and their relationships to postoperative clinical outcomes were compared. Results A total of 546 patients were enrolled in the analysis. The median IOF rate was 8.87 mL/kg/h. We divided the patients into two groups: a low fluid volume group (LFVG <8.87 mL/kg/h, n=273) and a high fluid volume group (HFVG ≥8.87 mL/kg/h, n=273). No statistically significant differences in postoperative clinical outcomes were found between LFVG and HFVG either before or after propensity score matching. Conclusions No effect of IOF administration on clinical outcomes in patients undergoing McKeown esophagogastrectomy was identified. Further high-quality studies examining the influence of IOF administration on clinical outcomes following McKeown esophagogastrectomy are still needed.
目的液体治疗是围手术期管理的关键组成部分之一。然而,术中液体(IOF)给药影响麦基翁食管胃切除术后临床结果的证据仍然有限。本研究调查了IOF对麦基翁食管胃切除术后临床结果的影响。方法对2013年7月至2016年7月期间接受麦基翁食管胃切除术的患者进行鉴定。从我们的电子医疗记录和麻醉记录中回顾性收集每个符合条件的患者的术前、术中和术后变量。测定IOF发生率,并比较其与术后临床结果的关系。结果共有546名患者被纳入分析。IOF的中位速率为8.87 mL/kg/h。我们将患者分为两组:低液量组(LFVG<8.87 mL/kg/h,n=273)和高液量组。在倾向评分匹配之前或之后,LFVG和HFVG的术后临床结果没有发现统计学上的显著差异。结论在接受麦基翁食管胃切除术的患者中,IOF给药对临床结果没有影响。还需要进一步的高质量研究来检查IOF给药对麦基翁食管胃切除术后临床结果的影响。
{"title":"Effect of intraoperative fluid administration on perioperative outcomes in patients undergoing McKeown esophagogastrectomy","authors":"Hongliang Wu, Wen Wang, Gefei Zhao, Q. Xue","doi":"10.21147/j.issn.1000-9604.2019.05.04","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2019.05.04","url":null,"abstract":"Objective Fluid therapy is one of the key components of perioperative management. However, evidence of intraoperative fluid (IOF) administration affecting clinical outcomes following McKeown esophagogastrectomy remains limited. This study investigated the impact of IOF on clinical outcomes after McKeown esophagogastrectomy. Methods Patients who underwent McKeown esophagogastrectomy between July 2013 and July 2016 were identified. Preoperative, intraoperative and postoperative variables for each eligible patient were retrospectively collected from our electronic medical records and anesthetic records. IOF rates were determined and their relationships to postoperative clinical outcomes were compared. Results A total of 546 patients were enrolled in the analysis. The median IOF rate was 8.87 mL/kg/h. We divided the patients into two groups: a low fluid volume group (LFVG <8.87 mL/kg/h, n=273) and a high fluid volume group (HFVG ≥8.87 mL/kg/h, n=273). No statistically significant differences in postoperative clinical outcomes were found between LFVG and HFVG either before or after propensity score matching. Conclusions No effect of IOF administration on clinical outcomes in patients undergoing McKeown esophagogastrectomy was identified. Further high-quality studies examining the influence of IOF administration on clinical outcomes following McKeown esophagogastrectomy are still needed.","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"31 1","pages":"742 - 748"},"PeriodicalIF":5.1,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47299661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical outcomes of hand-assisted laparoscopic liver resection vs. open liver resection: A retrospective propensity score-matched cohort study 手助腹腔镜肝切除术与开放性肝切除术的手术结果:一项回顾性倾向评分匹配队列研究
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2019-10-01 DOI: 10.21147/j.issn.1000-9604.2019.05.11
Shengtao Lin, Fan Wu, Liming Wang, Yunhe Liu, Yiling Zheng, Tana Siqin, W. Rong, Jianxiong Wu
Objective Hand-assisted laparoscopic liver resection has the advantages of open and laparoscopic surgeries. There is still lack of comparison of surgical outcomes between hand-assistied laparoscopic liver resection (HALLR) and open liver resection (OLR). This study compared the surgical outcomes of the two approaches between well-matched patient cohorts. Methods Patients who received liver resection during January 2014 and October 2017 in Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College were included in this retrospective study. Propensity score matching (PSM) was performed to reduce selection bias between the two groups. Operation and short-term surgical outcomes were compared between the well matched groups. Results During this period, 232 patients with a median age of 55.1 years old received OLR, while 49 patients with a median age of 54.7 years old received HALLR. Compared with HALLR group, OLR group has a higher proportion in male patients (190/232, 81.9% vs. 34/49, 69.4%, P=0.048) and lower albumin (43.2±4.5 vs. 44.8±3.7, P=0.020). After PSM, 49 patients from each group were included in the following analysis. Two groups were well balanced in their baseline characteristics, liver functions, preoperative treatments, abdominal surgery history, and surgical difficulty. None perioperative mortality was observed in both groups. Operation time and postoperative complications were similar in two groups (P=0.935, P=0.056). The HALLR group showed less bleeding amount (177.8±217.1 mL vs. 283.1±225.0 mL, P=0.003) and shorter postoperative stay period (6.9±2.2 d vs. 9.0±3.5 d, P=0.001). Conclusions We demonstrated that hand-assisted laparoscopic surgery is feasible and safe for liver resection, including some difficult cases. HALLR can provide better bleeding control and faster recovery after surgery.
目的手辅助腹腔镜肝切除术具有开放手术和腹腔镜手术的优点。手辅助腹腔镜肝切除术(HALLR)与开放肝切除术(OLR)的手术效果比较尚缺乏。本研究比较了两种方法在匹配良好的患者队列中的手术结果。方法回顾性研究2014年1月至2017年10月在中国医学科学院肿瘤医院和北京协和医学院行肝切除术的患者。采用倾向评分匹配(PSM)来减少两组间的选择偏倚。比较两组手术及短期手术效果。结果232例患者接受OLR治疗,中位年龄55.1岁,49例患者接受HALLR治疗,中位年龄54.7岁。与HALLR组相比,OLR组男性患者比例较高(190/232,81.9%比34/49,69.4%,P=0.048),白蛋白较低(43.2±4.5比44.8±3.7,P=0.020)。经PSM后,每组49例患者纳入以下分析。两组患者的基线特征、肝功能、术前治疗、腹部手术史和手术难度均平衡良好。两组患者围手术期均无死亡。两组手术时间及术后并发症相似(P=0.935, P=0.056)。HALLR组出血量少(177.8±217.1 mL比283.1±225.0 mL, P=0.003),术后住院时间短(6.9±2.2 d比9.0±3.5 d, P=0.001)。结论手辅助腹腔镜手术在肝切除术中是可行和安全的,包括一些困难的病例。HALLR可以更好地控制出血,术后恢复更快。
{"title":"Surgical outcomes of hand-assisted laparoscopic liver resection vs. open liver resection: A retrospective propensity score-matched cohort study","authors":"Shengtao Lin, Fan Wu, Liming Wang, Yunhe Liu, Yiling Zheng, Tana Siqin, W. Rong, Jianxiong Wu","doi":"10.21147/j.issn.1000-9604.2019.05.11","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2019.05.11","url":null,"abstract":"Objective Hand-assisted laparoscopic liver resection has the advantages of open and laparoscopic surgeries. There is still lack of comparison of surgical outcomes between hand-assistied laparoscopic liver resection (HALLR) and open liver resection (OLR). This study compared the surgical outcomes of the two approaches between well-matched patient cohorts. Methods Patients who received liver resection during January 2014 and October 2017 in Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College were included in this retrospective study. Propensity score matching (PSM) was performed to reduce selection bias between the two groups. Operation and short-term surgical outcomes were compared between the well matched groups. Results During this period, 232 patients with a median age of 55.1 years old received OLR, while 49 patients with a median age of 54.7 years old received HALLR. Compared with HALLR group, OLR group has a higher proportion in male patients (190/232, 81.9% vs. 34/49, 69.4%, P=0.048) and lower albumin (43.2±4.5 vs. 44.8±3.7, P=0.020). After PSM, 49 patients from each group were included in the following analysis. Two groups were well balanced in their baseline characteristics, liver functions, preoperative treatments, abdominal surgery history, and surgical difficulty. None perioperative mortality was observed in both groups. Operation time and postoperative complications were similar in two groups (P=0.935, P=0.056). The HALLR group showed less bleeding amount (177.8±217.1 mL vs. 283.1±225.0 mL, P=0.003) and shorter postoperative stay period (6.9±2.2 d vs. 9.0±3.5 d, P=0.001). Conclusions We demonstrated that hand-assisted laparoscopic surgery is feasible and safe for liver resection, including some difficult cases. HALLR can provide better bleeding control and faster recovery after surgery.","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"31 1","pages":"818 - 824"},"PeriodicalIF":5.1,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46371710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Distribution of high-risk human papillomavirus genotype prevalence and attribution to cervical precancerous lesions in rural North China 华北农村高危人乳头瘤病毒基因型流行分布及宫颈癌前病变归因
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2019-08-01 DOI: 10.21147/j.issn.1000-9604.2019.04.10
Shuang Zhao, Xuelian Zhao, Shangying Hu, Jessica Lu, X. Duan, Xun Zhang, Feng Chen, F. Zhao
Objective Precise prevention is more desired for cervical cancer due to the huge population, high prevalence of human papillomavirus (HPV) infection in China and the vision of screen-and-treat strategies in low- and middle-income countries (LMICs). Considerations of combining type-specific prevalence and attribution proportion to high-grade cervical intraepithelial neoplasia are informative to more precise and effective region-specific cervical cancer prevention and control programs. The aim of the current study was to determine the genotype distribution of HPV and attribution to cervical precancerous lesions among women from rural areas in North China. Methods A total of 9,526 women participated in the cervical cancer screening project in rural China. The samples of women who tested positive for HPV were retested with a polymerase chain reaction (PCR)-based HPV genotyping test. The attribution proportion of specific high-risk human papillomavirus (HR-HPV) types for different grades of cervical lesions was calculated by using the type contribution weighting method. Results A total of 22.2% (2,112/9,526) of women were HR-HPV positive and HPV52 (21.7%) was the most common HR-HPV genotype, followed by HPV58 (18.2%), HPV53 (18.2%) and HPV16 (16.2%). The top three genotypes detected in HR-HPV-positive cervical intraepithelial neoplasia (CIN)1 were HPV16 (36.7%), HPV58 (20.4%), HPV56 (15.3%). Among CIN2+, the most frequent genotypes were HPV16 (75.6%), HPV52 (17.8%), HPV58 (16.7%). HPV16, 56, 58, 53, 52, 59, 68, and 18 combined were attributed to 84.17% of all CIN1 lesions, and HPV16, 58, and 52 combined were attributed to 86.98% of all CIN2+ lesions. Conclusions The prevalence of HR-HPV infection among women from rural areas in North China was high and HPV16, HPV58, HPV52 had paramount attributable fraction in CIN2+. Type-specific HPV prevalence and attribution proportion to cervical precancerous lesions should be taken into consideration in the development of vaccines and strategy for screening in this population.
目的由于中国人口众多,人乳头瘤病毒(HPV)感染率高,以及中低收入国家(LMICs)对筛查和治疗策略的愿景,对宫颈癌的精确预防更为迫切。考虑结合类型特异性患病率和高级别宫颈上皮内瘤变的归因比例,可以为更精确和有效的区域特异性宫颈癌预防和控制计划提供信息。本研究的目的是确定中国北方农村地区妇女中HPV的基因型分布和宫颈癌前病变的归因。方法对9526名农村妇女进行宫颈癌筛查。对HPV检测呈阳性的妇女样本进行了基于聚合酶链反应(PCR)的HPV基因分型检测。采用类型贡献权重法计算不同级别宫颈病变特定高危型人乳头瘤病毒(HR-HPV)的归因比例。结果共有22.2%(2,112/9,526)的女性HR-HPV阳性,以HPV52基因型(21.7%)最为常见,其次是HPV58基因型(18.2%)、HPV53基因型(18.2%)和HPV16基因型(16.2%)。hr - hpv阳性宫颈上皮内瘤变(CIN)1中检出的前3位基因型分别为HPV16(36.7%)、HPV58(20.4%)、HPV56(15.3%)。在CIN2+中,最常见的基因型是HPV16(75.6%)、HPV52(17.8%)和HPV58(16.7%)。HPV16、56、58、53、52、59、68、18联合占所有CIN1病变的84.17%,HPV16、58、52联合占所有CIN2+病变的86.98%。结论华北农村妇女HR-HPV感染率较高,HPV16、HPV58、HPV52在CIN2+中占最大归因比例。在这一人群中开发疫苗和筛查策略时,应考虑特定类型的HPV患病率和宫颈癌前病变的归因比例。
{"title":"Distribution of high-risk human papillomavirus genotype prevalence and attribution to cervical precancerous lesions in rural North China","authors":"Shuang Zhao, Xuelian Zhao, Shangying Hu, Jessica Lu, X. Duan, Xun Zhang, Feng Chen, F. Zhao","doi":"10.21147/j.issn.1000-9604.2019.04.10","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2019.04.10","url":null,"abstract":"Objective Precise prevention is more desired for cervical cancer due to the huge population, high prevalence of human papillomavirus (HPV) infection in China and the vision of screen-and-treat strategies in low- and middle-income countries (LMICs). Considerations of combining type-specific prevalence and attribution proportion to high-grade cervical intraepithelial neoplasia are informative to more precise and effective region-specific cervical cancer prevention and control programs. The aim of the current study was to determine the genotype distribution of HPV and attribution to cervical precancerous lesions among women from rural areas in North China. Methods A total of 9,526 women participated in the cervical cancer screening project in rural China. The samples of women who tested positive for HPV were retested with a polymerase chain reaction (PCR)-based HPV genotyping test. The attribution proportion of specific high-risk human papillomavirus (HR-HPV) types for different grades of cervical lesions was calculated by using the type contribution weighting method. Results A total of 22.2% (2,112/9,526) of women were HR-HPV positive and HPV52 (21.7%) was the most common HR-HPV genotype, followed by HPV58 (18.2%), HPV53 (18.2%) and HPV16 (16.2%). The top three genotypes detected in HR-HPV-positive cervical intraepithelial neoplasia (CIN)1 were HPV16 (36.7%), HPV58 (20.4%), HPV56 (15.3%). Among CIN2+, the most frequent genotypes were HPV16 (75.6%), HPV52 (17.8%), HPV58 (16.7%). HPV16, 56, 58, 53, 52, 59, 68, and 18 combined were attributed to 84.17% of all CIN1 lesions, and HPV16, 58, and 52 combined were attributed to 86.98% of all CIN2+ lesions. Conclusions The prevalence of HR-HPV infection among women from rural areas in North China was high and HPV16, HPV58, HPV52 had paramount attributable fraction in CIN2+. Type-specific HPV prevalence and attribution proportion to cervical precancerous lesions should be taken into consideration in the development of vaccines and strategy for screening in this population.","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"31 1","pages":"663 - 672"},"PeriodicalIF":5.1,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46346278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Association of cancer prevention awareness with esophageal cancer screening participation rates: Results from a population-based cancer screening program in rural China 癌症预防意识与食管癌症筛查参与率的关系:中国农村基于人群的癌症筛查项目的结果
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2019-08-01 DOI: 10.21147/j.issn.1000-9604.2019.04.04
Shangchun Jia, He Li, H. Zeng, R. Zheng, Jiang Li, Jufang Shi, Zhixun Yang, M. Cao, Wanqing Chen
Objective China have implemented population-based esophageal cancer (EC) screening programs, however, the participant rates were relatively low. This study was conducted to examine the association between cancer prevention knowledge and EC screening participation rates (PRs). Methods Data in the analyses were obtained from a population-based cancer screening program in four provinces in China since 2007. In the course of 2007−2016, participants who were evaluated as high risk for EC and subsequently recommended for endoscopy examination were included in the final analysis. One-way analysis of variance test, Chi-square test and logistic regression analysis were applied. Results A total of 28,543 individuals assessed as high-risk population for EC were included in this study, with 13,036 males (45.67%) and 15,507 females (54.33%). The prevalence rates of current smoking and alcohol drinking were higher in males (58.25% and 44.22%, respectively) than in females (5.35% and 4.05%, respectively). Participants of females, and those who had older age, lower income, as well as higher education level and cancer prevention knowledge level were more likely to undergo endoscopy. Multivariable analysis showed that higher cancer prevention knowledge was associated with higher PR for endoscopic screening [adjusted odd ratio (aORQ4/Q1) =1.511, 95% confidence interval (95% CI): 1.398−1.632] among our study subjects. This association between cancer prevention knowledge and compliance with endoscopic screening also tends to be strong within subgroups of males, females, aged below 60 years, aged 60 years and above, and lower level of education (illiterate individuals and those with junior high education or less). Conclusions Our results displayed a positive relationship between cancer prevention knowledge and PRs for endoscopic screening, implying cancer prevention awareness being an independent influence factor for compliance with EC screening. Promoting public campaigns about comprehensive knowledge of cancer prevention seemed to be a reasonable and effective strategy to improve population PRs for EC screening.
目的我国已实施以人群为基础的癌症筛查项目,但参与率相对较低。本研究旨在检验癌症预防知识与EC筛查参与率(PR)之间的关系。方法自2007年以来,从中国四个省的癌症筛查项目中获得分析数据。在2007-2016年期间,被评估为EC高风险并随后建议进行内窥镜检查的参与者被纳入最终分析。采用单因素方差分析、卡方检验和逻辑回归分析。结果本研究共纳入28543名EC高危人群,其中男性13036人(45.67%),女性15507人(54.33%)。目前吸烟和饮酒的患病率男性(分别为58.25%和44.22%)高于女性(分别为5.35%和4.05%)。女性参与者以及年龄较大、收入较低、教育水平和癌症预防知识水平较高的参与者更有可能接受内窥镜检查。多因素分析显示,在我们的研究对象中,癌症预防知识越高,内窥镜筛查的PR越高[调整后的奇数比(aORQ4/Q1)=1.511,95%置信区间(95%CI):1.398−1.632]。癌症预防知识与内窥镜筛查依从性之间的这种关联在男性、女性、60岁以下、60岁及以上以及教育水平较低的人群(文盲和初中或初中以下)中也很强。结论癌症预防知识与内镜筛查的PRs呈正相关,提示癌症预防意识是EC筛查依从性的独立影响因素。促进公众宣传癌症预防的全面知识似乎是改善EC筛查人群PR的合理有效策略。
{"title":"Association of cancer prevention awareness with esophageal cancer screening participation rates: Results from a population-based cancer screening program in rural China","authors":"Shangchun Jia, He Li, H. Zeng, R. Zheng, Jiang Li, Jufang Shi, Zhixun Yang, M. Cao, Wanqing Chen","doi":"10.21147/j.issn.1000-9604.2019.04.04","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2019.04.04","url":null,"abstract":"Objective China have implemented population-based esophageal cancer (EC) screening programs, however, the participant rates were relatively low. This study was conducted to examine the association between cancer prevention knowledge and EC screening participation rates (PRs). Methods Data in the analyses were obtained from a population-based cancer screening program in four provinces in China since 2007. In the course of 2007−2016, participants who were evaluated as high risk for EC and subsequently recommended for endoscopy examination were included in the final analysis. One-way analysis of variance test, Chi-square test and logistic regression analysis were applied. Results A total of 28,543 individuals assessed as high-risk population for EC were included in this study, with 13,036 males (45.67%) and 15,507 females (54.33%). The prevalence rates of current smoking and alcohol drinking were higher in males (58.25% and 44.22%, respectively) than in females (5.35% and 4.05%, respectively). Participants of females, and those who had older age, lower income, as well as higher education level and cancer prevention knowledge level were more likely to undergo endoscopy. Multivariable analysis showed that higher cancer prevention knowledge was associated with higher PR for endoscopic screening [adjusted odd ratio (aORQ4/Q1) =1.511, 95% confidence interval (95% CI): 1.398−1.632] among our study subjects. This association between cancer prevention knowledge and compliance with endoscopic screening also tends to be strong within subgroups of males, females, aged below 60 years, aged 60 years and above, and lower level of education (illiterate individuals and those with junior high education or less). Conclusions Our results displayed a positive relationship between cancer prevention knowledge and PRs for endoscopic screening, implying cancer prevention awareness being an independent influence factor for compliance with EC screening. Promoting public campaigns about comprehensive knowledge of cancer prevention seemed to be a reasonable and effective strategy to improve population PRs for EC screening.","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"31 1","pages":"601 - 608"},"PeriodicalIF":5.1,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47872055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018 (English version) 中国恶性淋巴瘤诊疗指南2018(英文版)
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2019-08-01 DOI: 10.21147/j.issn.1000-9604.2019.04.01
National Health Commission of PRC
1. Overview 2. Diagnosis of lymphoma 2.1 Clinical manifestations 2.2 Physical examination 2.3 Laboratory examination 2.4 Imaging examination 2.4.1 CT 2.4.2 MRI 2.4.3 PET-CT 2.4.4 Ultrasound 2.4.5 Isotope bone scan 2.5 Other specific examinations 2.6 Pathological examinations 2.6.1 Morphology 2.6.2 IHC 2.6.3 Fluorescence in situ hybridization (FISH) 2.6.4 Antigen receptor gene rearrangement of lymphocytes 2.6.5 Others 3. Staging of lymphoma 4. Radiotherapy of lymphoma 5. Summary of comprehensive treatment of lymphoma 6. Treatment of lymphoma with Traditional Chinese Medicine 7. Clinical features, diagnosis and treatment of common lymphoma pathological types 7.1 HL 7.1.1 Clinical features 7.1.2 Pathological classification and diagnosis 7.1.3 Treatment principles 7.1.4 Prognostic factors of HL 7.2 NHL 7.2.1 DLBCL 7.2.2 FL 7.2.3 MZL 7.2.4 CLL/SLL 7.2.5 MCL 7.2.6 BL 7.2.7 Lymphoblastic lymphoma (LBL) 7.2.8 Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) 7.2.9 Mycosis fungoides/Sézary syndrome, MF/SS 7.2.10 ENKTL 1. Overview
1.概述2。淋巴瘤的诊断2.1临床表现2.2体格检查2.3实验室检查2.4影像学检查2.4.1 CT 2.4.2 MRI 2.4.3 PET-CT 2.4.4超声2.4.5同位素骨扫描2.5其他特异性检查2.6病理学检查2.6.1形态学2.6.2 IHC 2.6.3荧光原位杂交(FISH)2.6.4淋巴细胞抗原受体基因重排2.6.5其他3。淋巴瘤的分期4。淋巴瘤的放射治疗5。淋巴瘤综合治疗总结6。淋巴瘤的中医治疗7。常见淋巴瘤的临床特征、诊断和治疗病理类型7.1 HL 7.1.1临床特征7.1.2病理分类和诊断7.1.3治疗原则7.1.4 HL的预后因素7.2 NHL 7.2.1 DLBCL 7.2.2 FL 7.2.3 MZL 7.2.4 CLL/SLL 7.2.5 MCL 7.2.6 BL 7.2.7淋巴母细胞淋巴瘤(LBL)7.2.8外周T细胞淋巴瘤,未另行说明(PTCL-NOS)7.2.9蕈样肉芽肿/Sézary综合征,MF/SS 7.2.10 ENKTL 1。概述
{"title":"Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018 (English version)","authors":"National Health Commission of PRC","doi":"10.21147/j.issn.1000-9604.2019.04.01","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2019.04.01","url":null,"abstract":"1. Overview 2. Diagnosis of lymphoma 2.1 Clinical manifestations 2.2 Physical examination 2.3 Laboratory examination 2.4 Imaging examination 2.4.1 CT 2.4.2 MRI 2.4.3 PET-CT 2.4.4 Ultrasound 2.4.5 Isotope bone scan 2.5 Other specific examinations 2.6 Pathological examinations 2.6.1 Morphology 2.6.2 IHC 2.6.3 Fluorescence in situ hybridization (FISH) 2.6.4 Antigen receptor gene rearrangement of lymphocytes 2.6.5 Others 3. Staging of lymphoma 4. Radiotherapy of lymphoma 5. Summary of comprehensive treatment of lymphoma 6. Treatment of lymphoma with Traditional Chinese Medicine 7. Clinical features, diagnosis and treatment of common lymphoma pathological types 7.1 HL 7.1.1 Clinical features 7.1.2 Pathological classification and diagnosis 7.1.3 Treatment principles 7.1.4 Prognostic factors of HL 7.2 NHL 7.2.1 DLBCL 7.2.2 FL 7.2.3 MZL 7.2.4 CLL/SLL 7.2.5 MCL 7.2.6 BL 7.2.7 Lymphoblastic lymphoma (LBL) 7.2.8 Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) 7.2.9 Mycosis fungoides/Sézary syndrome, MF/SS 7.2.10 ENKTL 1. Overview","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"31 1","pages":"557 - 577"},"PeriodicalIF":5.1,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43320854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
期刊
Chinese Journal of Cancer Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1